Zobrazeno 1 - 10
of 289
pro vyhledávání: '"Luc, Biedermann"'
Autor:
Jeanine Wakim El-Khoury, Ekaterina Safroneeva, Catherine Saner, Jean-Benoit Rossel, Sven Trelle, Marcel Zwahlen, Luc Biedermann, Andrea Kreienbuehl, Thomas Greuter, Philipp Schreiner, Peter Netzer, Annett Franke, Stephan Brand, Chantal Hasler, Patrick Aepli, Emanuel Burri, Achim Weber, Christine Sempoux, Ruggero Biral, Wolfram Jochum, Joachim Diebold, Niels Willi, Alex Straumann, Alain M. Schoepfer
Publikováno v:
Inflammatory Intestinal Diseases, Vol 9, Iss 1, Pp 165-173 (2024)
Introduction: The Swiss Eosinophilic Esophagitis Cohort Study (SEECS) is a national cohort that was established in 2015 with the aim of improving quality of care of affected adults with eosinophilic esophagitis (EoE). Between 2020 and 2022, paper que
Externí odkaz:
https://doaj.org/article/9cc813641253435cb4165babb8fda911
Autor:
Andrea Kreienbuehl, Gerhard Rogler, Burri Emanuel, Luc Biedermann, Christian Meier, Pascal Juillerat, Sophie Restellini, Peter Hruz, Stefan R. Vavricka, Daniel Aeberli, Frank Seibold
Publikováno v:
Swiss Medical Weekly, Vol 154, Iss 6 (2024)
Patients with inflammatory bowel disease (IBD) are prone to reduced bone mineral density and elevated overall fracture risk. Osteopenia affects up to 40% of patients with IBD (high regional variability). Besides disease activity, IBD specialists must
Externí odkaz:
https://doaj.org/article/e62a86297c764765b3bb445ce1658d35
Autor:
Severin A. Lautenschlager, Mamadou Pathé Barry, Gerhard Rogler, Luc Biedermann, Philipp Schreiner, Alexander R. Siebenhüner, Swiss IBD Cohort Study Group
Publikováno v:
BMC Gastroenterology, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Background Various environmental risk factors have been associated with the pathogenesis of inflammatory bowel disease. In this study we aimed to identify lifestyle factors that affect the onset of Crohn’s disease and ulcerative colitis. M
Externí odkaz:
https://doaj.org/article/050e64a7b7204c5d8e745f68f1130a31
Autor:
Brian M. Lang, Martina Ledergerber, Sebastian Bruno Ulrich Jordi, Niklas Krupka, Luc Biedermann, Philipp Schreiner, Pascal Juillerat, Jacqueline Wyss, Stephan R. Vavricka, Jonas Zeitz, Roland von Känel, Gerhard Rogler, Niko Beerenwinkel, Benjamin Misselwitz
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 16 (2023)
Background: While the detrimental impact of negative emotions on the clinical course of inflammatory bowel disease (IBD) and quality of life has been extensively investigated, evidence for a potential impact of positive emotions is scarce. Objectives
Externí odkaz:
https://doaj.org/article/821caaed25dc40018285a2c701013436
Autor:
Priyatharsan Yoganathan, Jean-Benoit Rossel, Sebastian Bruno Ulrich Jordi, Yannick Franc, Luc Biedermann, Benjamin Misselwitz, Martin Hausmann, Gerhard Rogler, Michael Scharl, Isabelle Frey-Wagner, Swiss IBD cohort study group
Publikováno v:
BMC Gastroenterology, Vol 21, Iss 1, Pp 1-16 (2021)
Abstract Background Genetic variations within the regulatory region of the gene encoding NOD-like receptor pyrin domain containing 3 (NLRP3) have been associated with Crohn’s Disease (CD). NLRP3 is part of the NLRP3-inflammasome that mediates the m
Externí odkaz:
https://doaj.org/article/b94c4b271008421dae595d75da0c1a55
Autor:
Martina Ledergerber, Brian M. Lang, Henriette Heinrich, Luc Biedermann, Stefan Begré, Jonas Zeitz, Niklas Krupka, Andreas Rickenbacher, Matthias Turina, Thomas Greuter, Philipp Schreiner, René Roth, Alexander Siebenhüner, Stephan R. Vavricka, Gerhard Rogler, Niko Beerenwinkel, Benjamin Misselwitz, the Swiss IBD Cohort Study Group
Publikováno v:
BMC Gastroenterology, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background Abdominal pain is a frequent symptom in patients with inflammatory bowel disease (IBD) including Crohn’s disease (CD) and ulcerative colitis (UC). Pain can result from ongoing inflammation or functional disorders imitating irrit
Externí odkaz:
https://doaj.org/article/99fb7581359447d1a6f178e77e52a37f
Autor:
Ilana Reinhold, Sena Blümel, Jens Schreiner, Onur Boyman, Jan Bögeholz, Marcus Cheetham, Gerhard Rogler, Luc Biedermann, Michael Scharl
Publikováno v:
Inflammatory Intestinal Diseases, Pp 1-10 (2020)
Background and Aims: The majority of patients treated with anti-tumor necrosis factor (TNF) therapy develop anti-drug antibodies (ADAs), which might result in loss of treatment efficacy. Strict guidelines on measuring trough levels (TLs) and ADA in c
Externí odkaz:
https://doaj.org/article/a072f0b8ec674099b08f26b40c8fe964
Autor:
Kathrin Perrig, Niklas Krupka, Sebastian Bruno Ulrich Jordi, Jean-Benoît Rossel, Luc Biedermann, Thomas Greuter, Philipp Schreiner, Stephan R. Vavricka, Pascal Juillerat, Emanuel Burri, Dorothee Zimmermann, Michel H. Maillard, Michael Christian Sulz, Stephan Brand, Gerhard Rogler, Benjamin Misselwitz
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 15 (2022)
Background: Tumor necrosis factor (TNF) inhibitors have improved treatment of ulcerative colitis (UC), but loss of response remains a frequent problem. The anti-TNF agent, golimumab, was approved in Switzerland for the treatment of UC in 2014. This s
Externí odkaz:
https://doaj.org/article/3dc3da4e952b4b73bcb7635cd040ba58
Autor:
Severin A. Lautenschlager, Nicolas Fournier, Luc Biedermann, Valerie Pittet, Philipp Schreiner, Benjamin Misselwitz, Michael Scharl, Gerhard Rogler, Alexander R. Siebenhüner
Publikováno v:
Inflammatory Intestinal Diseases, Pp 1-10 (2020)
Introduction: The pathophysiology of inflammatory bowel disease (IBD) is incompletely understood. Current concepts imply that environmental factors (EFs) trigger disease onset as well as flares in genetically susceptible individuals. Objective: The o
Externí odkaz:
https://doaj.org/article/cb23b8db819e4b1abce32373faa5d16a
Autor:
Julian Burla, Sena Bluemel, Luc Biedermann, Marjam J. Barysch, Reinhard Dummer, Mitchell P. Levesque, Christoph Gubler, Bernhard Morell, Gerhard Rogler, Michael Scharl
Publikováno v:
Inflammatory Intestinal Diseases, Pp 1-8 (2020)
Background/Aims: Among the severe immune-related adverse events (irAEs) that occur with immune checkpoint inhibitor (ICI) therapy, colitis is the most frequent one. This study aimed at describing the experience from the largest gastroenterology unit
Externí odkaz:
https://doaj.org/article/8d2c10a9ebeb43e5957df3593ca2c0ea